Pages that link to "Q43961558"
Jump to navigation
Jump to search
The following pages link to Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (Q43961558):
Displaying 50 items.
- Applications of CYP450 testing in the clinical setting (Q24621760) (← links)
- Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide (Q24651117) (← links)
- Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination (Q24670563) (← links)
- Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents (Q26751138) (← links)
- Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy (Q28080752) (← links)
- Pharmacogenomics and drug response in cardiovascular disorders (Q28171051) (← links)
- Personalized medicine in Type 2 Diabetes (Q28542708) (← links)
- A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan (Q28551748) (← links)
- Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells (Q29347062) (← links)
- Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? (Q30388214) (← links)
- Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data (Q30571118) (← links)
- Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment (Q31144283) (← links)
- Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. (Q33430638) (← links)
- Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat (Q33555327) (← links)
- Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing (Q33779389) (← links)
- Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms (Q33813015) (← links)
- CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases (Q33984240) (← links)
- Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective (Q33993320) (← links)
- Pharmacogenetics of Anti-Diabetes Drugs (Q34181995) (← links)
- Implications of pharmacogenetics for individualizing drug treatment and for study design (Q35102211) (← links)
- Pharmacokinetic interactions with rifampicin : clinical relevance (Q35185727) (← links)
- Contributions of human cytochrome P450 enzymes to glyburide metabolism (Q35210475) (← links)
- Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19 (Q35211432) (← links)
- Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors (Q35551835) (← links)
- Clinical relevance of genetic polymorphisms in the human CYP2C9 gene (Q35594567) (← links)
- Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects (Q35825729) (← links)
- Pharmacogenetics in type 2 diabetes: potential implications for clinical practice (Q35840645) (← links)
- Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation (Q35952687) (← links)
- Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide (Q36024467) (← links)
- Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance (Q36350528) (← links)
- Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite (Q36639493) (← links)
- Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects (Q36792740) (← links)
- Pharmacogenetics of glucose-lowering drug treatment: a systematic review (Q36982648) (← links)
- A note on population analysis of dissolution-absorption models using the inverse Gaussian function (Q37111029) (← links)
- Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. (Q37194756) (← links)
- Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice (Q37198235) (← links)
- CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients (Q37227417) (← links)
- Pharmacogenetics of oral antidiabetic drugs. (Q37353476) (← links)
- Pharmacogenetics in diabetes (Q37424309) (← links)
- Pharmacogenetics and personalized treatment of type 2 diabetes (Q37508445) (← links)
- Cytochrome P450 2C9-CYP2C9. (Q37691210) (← links)
- Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide (Q37695883) (← links)
- Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics (Q37822185) (← links)
- Clinical pharmacokinetics and pharmacodynamics of vildagliptin (Q37984567) (← links)
- CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects (Q38059889) (← links)
- Genetics of type 2 diabetes and potential clinical implications (Q38078821) (← links)
- The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs (Q38110432) (← links)
- Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here? (Q38270699) (← links)
- Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes (Q38327711) (← links)
- Genetics of drug response in type 2 diabetes (Q38480670) (← links)